Bone Density Conservation Agents
"Bone Density Conservation Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
| Descriptor ID |
D050071
|
| MeSH Number(s) |
D27.505.696.242
|
| Concept/Terms |
Antiresorptive Agents- Antiresorptive Agents
- Bone Resorption Inhibitors
- Inhibitors, Bone Resorption
- Resorption Inhibitors, Bone
- Bone Resorption Inhibitory Agents
- Antiresorptive Drugs
|
Below are MeSH descriptors whose meaning is more general than "Bone Density Conservation Agents".
Below are MeSH descriptors whose meaning is more specific than "Bone Density Conservation Agents".
This graph shows the total number of publications written about "Bone Density Conservation Agents" by people in this website by year, and whether "Bone Density Conservation Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 4 | 1 | 5 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 1 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 5 | 1 | 6 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Bone Density Conservation Agents" by people in Profiles.
-
Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians (Version 1, Update Alert). Ann Intern Med. 2024 06; 177(6):eL230113.
-
Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023 Feb; 176(2):224-238.
-
Risk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years. BMC Musculoskelet Disord. 2020 Dec 03; 21(1):801.
-
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply. N Engl J Med. 2020 11 26; 383(22):2189-2190.
-
Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 08 20; 383(8):743-753.
-
Fracture Risk During and After Bisphosphonate Drug Holidays: A Matter of Methods? Med Care. 2020 05; 58(5):417-418.
-
The Epidemiology of Metatarsal Fractures Among Older Females With Bisphosphonate Exposure. J Foot Ankle Surg. 2020 Mar - Apr; 59(2):269-273.
-
Determinants of Oral Bisphosphonate Use Beyond 5 Years. J Manag Care Spec Pharm. 2020 Feb; 26(2):197-202.
-
Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2020 01; 167(1):144-148.
-
Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure. Osteoporos Int. 2019 Dec; 30(12):2515-2520.